U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts

Alnylam Pharmaceuticals

Market Cap: US$30.0b

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Insmed

Market Cap: US$28.9b

Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

Summit Therapeutics

Market Cap: US$12.1b

A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.

Praxis Precision Medicines

Market Cap: US$10.8b

A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.

Ionis Pharmaceuticals

Market Cap: US$9.4b

A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.

Vaxcyte

Market Cap: US$8.9b

A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

ImmunityBio

Market Cap: US$8.2b

A biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.

Definium Therapeutics

Market Cap: US$5.7b

A clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders.

CRISPR Therapeutics

Market Cap: US$5.2b

A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.

Dyne Therapeutics

Market Cap: US$4.9b

A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.

Celcuity

Market Cap: US$4.5b

A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.

Tango Therapeutics

Market Cap: US$4.3b

A precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.

Legend Biotech

Market Cap: US$4.0b

Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.

Viking Therapeutics

Market Cap: US$4.0b

A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Structure Therapeutics

Market Cap: US$3.7b

A clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.

NewAmsterdam Pharma

Market Cap: US$3.3b

A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.

Alumis

Market Cap: US$3.3b

A clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.

AbCellera Biologics

Market Cap: US$3.2b

Engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

BioCryst Pharmaceuticals

Market Cap: US$2.7b

A biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.

Beam Therapeutics

Market Cap: US$2.7b

A biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.

Ultragenyx Pharmaceutical

Market Cap: US$2.6b

A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.

Viridian Therapeutics

Market Cap: US$2.6b

Engages in discovering, developing, and commercializing treatments for serious and rare diseases.

Nektar Therapeutics

Market Cap: US$2.6b

A biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.

Trevi Therapeutics

Market Cap: US$2.5b

A clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.

Precigen

Market Cap: US$2.5b

A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.

Kailera Therapeutics

Market Cap: US$2.4b

Operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.

Mineralys Therapeutics

Market Cap: US$2.4b

A biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.

SELLAS Life Sciences Group

Market Cap: US$2.4b

A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.

Nuvation Bio

Market Cap: US$2.3b

A clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.

Ocular Therapeutix

Market Cap: US$2.2b

A biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.

ADMA Biologics

Market Cap: US$2.2b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Vera Therapeutics

Market Cap: US$2.2b

A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.

Biohaven

Market Cap: US$2.2b

A biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.

Stoke Therapeutics

Market Cap: US$2.1b

Engages in the development of treatments for severe genetic diseases by upregulating protein expression.

Taysha Gene Therapies

Market Cap: US$2.1b

A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.

Kardigan

Market Cap: US$2.0b

Operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases.